← Back to headlines
BioMarin's BMN 401 Trial Meets Endpoint
BioMarin announced that its Phase 3 trial for BMN 401, a treatment for ENPP1 Deficiency, successfully met one of its co-primary endpoints.
21 May, 13:29 — 21 May, 13:29
Sources
Showing 1 of 1 sources
